Annovis Bio (ANVS) Other Non Operating Income (2019 - 2026)
Annovis Bio (ANVS) posted Other Non Operating Income of $268000.0 for Q1 2026, up 190.54% sequentially from -$296000.0 in Q4 2025, and down 51.97% YoY from $558000.0 in Q1 2025.
Annovis Bio (ANVS) Other Non Operating Income (2019 - 2026) Analysis & Trends
Annovis Bio has reported Other Non Operating Income for 6 years, with the latest figure at $268000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 51.97% year-over-year to $268000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$148000.0 (up 96.61% YoY) and the FY2025 annual result came in at $142000.0, down 91.99% from the prior year.
- Other Non Operating Income improved to $268000.0 in Q1 2026 per ANVS's latest filing, from -$296000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $6.7 million in Q1 2024 and troughed at -$8.4 million in Q3 2024.
- A 3-year average of $242522.7 and a median of $268000.0 in 2026 frame the typical range for Other Non Operating Income.
- The widest YoY moves for Other Non Operating Income: up 100.24% in 2025, down 139.79% in 2025.
- Over 3 years, Other Non Operating Income stood at $743940.0 in 2024, then sank by 139.79% to -$296000.0 in 2025, then soared by 190.54% to $268000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered $268000.0, -$296000.0, and $20000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Annovis Bio | 67.91 Mn | 67.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 268,000.00 |
| Dec 31, 2025 | -296,000.00 |
| Sep 30, 2025 | 20,000.00 |
| Jun 30, 2025 | -140,000.00 |
| Mar 31, 2025 | 558,000.00 |
| Dec 31, 2024 | 743,940.00 |
| Sep 30, 2024 | -8.39 Mn |
| Jun 30, 2024 | 2.72 Mn |
| Mar 31, 2024 | 6.70 Mn |
| Jun 30, 2021 | 7,414.00 |
| Mar 31, 2021 | 29,340.00 |
| Dec 31, 2020 | 204,847.00 |
| Sep 30, 2020 | 586,903.00 |
| Jun 30, 2020 | 208,261.00 |
| Mar 31, 2020 | -26,500.00 |
| Dec 31, 2019 | -53,000.00 |
| Jun 30, 2019 | -26,500.00 |